TD Asset Management Inc Sells 152,698 Shares of Stryker Corporation $SYK

TD Asset Management Inc trimmed its stake in shares of Stryker Corporation (NYSE:SYK) by 13.3% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 995,155 shares of the medical technology company’s stock after selling 152,698 shares during the quarter. TD Asset Management Inc owned approximately 0.26% of Stryker worth $367,879,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Clayton Financial Group LLC acquired a new position in shares of Stryker in the 3rd quarter worth approximately $26,000. Elevation Point Wealth Partners LLC acquired a new position in shares of Stryker in the 2nd quarter valued at about $28,000. Kilter Group LLC bought a new stake in shares of Stryker during the 2nd quarter valued at about $29,000. Howard Hughes Medical Institute acquired a new stake in Stryker during the second quarter worth approximately $29,000. Finally, ANTIPODES PARTNERS Ltd bought a new stake in Stryker in the third quarter worth approximately $34,000. 77.09% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

SYK has been the subject of several recent analyst reports. Barclays reaffirmed an “overweight” rating and set a $469.00 price objective on shares of Stryker in a research report on Monday, February 2nd. William Blair started coverage on shares of Stryker in a report on Friday. They issued an “outperform” rating for the company. Wall Street Zen raised shares of Stryker from a “hold” rating to a “buy” rating in a research note on Saturday. Robert W. Baird set a $437.00 price objective on shares of Stryker in a research report on Friday, January 30th. Finally, Citigroup reaffirmed a “market outperform” rating on shares of Stryker in a research report on Friday, January 30th. Thirteen analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $426.47.

Stryker Trading Down 0.8%

NYSE:SYK opened at $381.84 on Wednesday. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.89 and a quick ratio of 1.21. Stryker Corporation has a one year low of $329.16 and a one year high of $404.87. The company has a market cap of $146.13 billion, a PE ratio of 45.46, a PEG ratio of 2.25 and a beta of 0.87. The firm has a 50-day moving average of $361.24 and a 200-day moving average of $368.91.

Stryker (NYSE:SYK) last released its quarterly earnings results on Thursday, January 29th. The medical technology company reported $4.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.40 by $0.07. The business had revenue of $7.17 billion during the quarter, compared to the consensus estimate of $7.12 billion. Stryker had a return on equity of 24.41% and a net margin of 12.92%.The company’s quarterly revenue was up 11.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $4.01 EPS. As a group, equities research analysts expect that Stryker Corporation will post 13.47 EPS for the current fiscal year.

Stryker Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, April 30th. Stockholders of record on Tuesday, March 31st will be issued a $0.88 dividend. The ex-dividend date is Tuesday, March 31st. This represents a $3.52 annualized dividend and a dividend yield of 0.9%. Stryker’s dividend payout ratio is currently 41.90%.

Insider Transactions at Stryker

In other Stryker news, Director Ronda E. Stryker sold 250,000 shares of the stock in a transaction dated Wednesday, February 4th. The shares were sold at an average price of $362.92, for a total value of $90,730,000.00. Following the completion of the sale, the director owned 2,457,331 shares in the company, valued at approximately $891,814,566.52. This trade represents a 9.23% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 5.20% of the company’s stock.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.